Option chain shows key data for NuCana's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NuCana.

NuCana (NASDAQ:NCNA) Stock, Option Chain

NuCana

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMLI

ATCH

CNTM

CNXC

GSX Techedu Inc. American Depositary Shares

GOTU

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

Kintara Therapeutics, Inc. - Common Stock

KTRA

MDXH

NCNA

NLSP

SEEL

SONN

SONO

TBIO

VSME

Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket

Crude Oil 6- logo

Equities

Eurozone

Commodities

Intraday Update

ASND

ITOS

NUVL

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Screenshot 2024-09-16 at 5.51.32 PM

Earnings

BBLG

DRMA

IMMP

NWTN

Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September

NuCana PLC

Treasuries

STKH

Steakholder Foods Announced That Its Board Of Directors Has Approved The Purchase Of Up To $1M In Cryptocurrency As Treasury Reserve Assets For The Company

Viant And Disney Advertising Partner To Enhance Addressability And Scale For Streaming Audiences, Leveraging Clean Room Technology And AI-Powered Solutions For Up To 20% Campaign Performance Improvement

Cantor Fitzgerald analyst Yi Fu Lee maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Overweight and raises the price target from $350 to $370.

Price Target

Analyst Ratings

CRWD

Cantor Fitzgerald Maintains Overweight on CrowdStrike Holdings, Raises Price Target to $370

Barclays analyst Jeffrey Bernstein maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Equal-Weight and raises the price target from $46 to $50.

JACK

Barclays Maintains Equal-Weight on Jack In The Box, Raises Price Target to $50

Flywire's integrated offering with Blackbaud will provide international students studying at over 1,000 U.S. independent schools with a streamlined payment experience, from enrollment through to tuition
Partnership strengthens Flywire's commitment to the K-12 education market in the United States

BLKB

FLYW

Flywire Partners With Blackbaud To Streamline Tuition Payment Experience for International K-12 Students In U.S.

Contracts

EDRY

EuroDry Signs $71.8M Contract With Nantong Xiangyu Shipbuilding For Two 63,500 DWT Ultramax Bulk Carriers, With Delivery Expected In Q2 And Q3 2027

BTOG

Bit Origin Received Non-Compliance Notification From Nasdaq

WIIM

LMFA

LM Funding America shares are trading higher after the company provided a monthly Bitcoin update and announced its holdings were valued at $13.3 million.

<a href="https://www.theinformation.com/articles/marketing-software-firm-braze-could-be-a-hot-acquisition-target" title="https://www.theinformation.com/articles/marketing-software-firm-braze-could-be-a-hot-acquisition-target">https://www.theinformation.com/articles/marketing-software-firm-braze-could-be-a-hot-acquisition-target</a>

BRZE

'Marketing Software Firm Braze Could Be A Hot Acquisition Target' - The Information

Barclays analyst Brian Morton maintains Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) with a Underweight and raises the price target from C$77 to C$85.

TSX:CM

Barclays Maintains Underweight on Canadian Imperial Bank, Raises Price Target to C$85

NYSE Grants DDC Enterprise Extension For Filing 2023 Annual Report On Form 20-F Through Feb. 4, 2025

DXC Technology And ServiceNow Expand Partnership To Launch Center Of Excellence, Accelerating Generative AI Adoption And Value For Businesses Globally

Barclays analyst Alex Scott maintains Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) with a Equal-Weight and raises the price target from $108 to $119.

Barclays Maintains Equal-Weight on Brown & Brown, Raises Price Target to $119

Shoe Carnival, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) reported third-quarter adjusted earnings per share of 71 cents, beating the street view of 67 cents.
Quarterly sales of $306.89 million missed<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42107205/shoe-carnival-reports-third-quarter-fiscal-2024-results" rel="noreferrer noopener"> the analyst consensus estimate of $316.95 million.</a>
Quarterly sales reflected the impact of the retail calendar shift that resulted in approximately $20 million of net sales moving out of the third quarter of 2024 compared to the prior year.
Without the impact of the retail calendar shift, net sales increased by 2.2% versus the prior year.
&#8220;Our flexible digital-first marketing campaign and great brand assortment drove demand during this peak shopping period and profitability in line with expectations for the third quarter,&#8221; said Mark Worden, President and Chief Executive Officer.
Comparable store net sales dropped 4.1% for the quarter, impacted by two hurricanes disrupting operations and warm weather delaying winter boot sales.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42107863/us-futures-head-lower-as-nvidia-reports-slowdown-in-quarterly-revenue-growth-expert-says-market-weakness-is-perfectly-normal-but-late-november-is-still-possible" rel="noreferrer noopener">US Futures Head Lower As Nvidia Earnings Fail To Impress Investors: Expert Says Market Weakness Is &#8216;Perfectly Normal,&#8217; But Late November Rally Is Still Possible</a>
Gross profit margin for the quarter was 36.0%, marking the 15th consecutive quarter above 35%, but was 80 basis points lower than last year.
The company continues to expect Rogan&#8217;s acquisition to deliver net sales of over $80 million in fiscal 2024, with $22.3 million of net sales in the third quarter of 2024 and $63.9 million year-to-date in 2024.
As of November 21, the company operated 431 stores, with 361 Shoe Carnival stores, 42 Shoe Station stores and the 28 Rogan&#8217;s locations. One new Shoe Station store opened in third quarter was in Tennessee, expanding this banner into a new market.
At the end of third quarter, the company had approximately $91.1 million of cash, cash equivalents and marketable securities.
Outlook: Shoe Carnival lowered its FY24 net sales outlook to $1.20 billion &#8211; $1.23 billion (estimate: $1.23 billion), down from the previously expected $1.23 billion &#8211; $1.25 billion, but maintains adjusted EPS guidance of <a href="https://www.benzinga.com/calendars/guidance">$2.60 &#8211; $2.75 (estimate: $2.63).</a>
Price Action: SCVL shares are trading higher by 1.25% to $33.89 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly" target="_blank" rel="noreferrer noopener">Target Says Shoppers Wait For &#8216;Deals&#8217; A Day After Rival Walmart Credits Market Gains To Wealthy Households</a></li>
</ul>

Guidance

General

SCVL

Shoe Carnival Q3: EPS Win But Sales Slip Amid Calendar Shifts And Weather Woes

DRIO

DarioHealth shares are trading higher after the company announced it signed four contracts with self-insured employers.

ALBT

Avalon GloboCare Regains Nasdaq Compliance

5 analysts have shared their evaluations of STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $33.4, a high estimate of $36.00, and a low estimate of $30.00. Experiencing a 12.11% decline, the current average is now lower than the previous average price target of $38.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1732197625_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive STMicroelectronics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Maintains</td>
<td>Positive</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Anthony Stoss</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$35.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to STMicroelectronics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of STMicroelectronics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for STMicroelectronics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of STMicroelectronics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on STMicroelectronics analyst ratings.</a>
<h2>Get to Know STMicroelectronics Better</h2>
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
<h3>Unraveling the Financial Story of STMicroelectronics</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining STMicroelectronics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -26.63% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: STMicroelectronics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.8% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): STMicroelectronics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): STMicroelectronics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.37%, the company may face hurdles in achieving optimal financial performance.
Debt Management: STMicroelectronics's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For STMicroelectronics's Future

Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-22. Here's what investors need to know before the announcement.
Analysts estimate that Destination XL Group will report an earnings per share (EPS) of $0.03. 
The market awaits Destination XL Group's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.05, leading to a 1.1% increase in the share price on the subsequent day.
Here's a look at Destination XL Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.09</td>
<td>0.04</td>
<td>0.06</td>
<td>0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.04</td>
<td>0.06</td>
<td>0.10</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>8.0%</td>
<td>2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732197623_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Destination XL Group were trading at $2.5 as of November 19. Over the last 52-week period, shares are down 37.66%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Destination XL Group</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Destination XL Group.
The consensus rating for Destination XL Group is Buy, derived from 1 analyst ratings. An average one-year price target of $4.0 implies a potential 60.0% upside.
<h3>Comparing Ratings with Competitors</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of ThredUp, Citi Trends and Tilly's, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, ThredUp is favoring an Outperform trajectory, with an average 1-year price target of $3.0, suggesting a potential 20.0% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Citi Trends, with an average 1-year price target of $17.0, implying a potential 580.0% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Tilly's, with an average 1-year price target of $6.0, suggesting a potential 140.0% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for ThredUp, Citi Trends and Tilly's are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Destination XL Group</td>
<td>Buy</td>
<td>-10.87%</td>
<td>$60.17M</td>
<td>1.53%</td>
</tr>
<tr>
<td>ThredUp</td>
<td>Outperform</td>
<td>-11.00%</td>
<td>$51.98M</td>
<td>-31.81%</td>
</tr>
<tr>
<td>Citi Trends</td>
<td>Buy</td>
<td>1.73%</td>
<td>$54.93M</td>
<td>-12.64%</td>
</tr>
<tr>
<td>Tilly's</td>
<td>Neutral</td>
<td>1.82%</td>
<td>$49.92M</td>
<td>-0.05%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Destination XL Group ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is at the top for Return on Equity.
<h3>About Destination XL Group</h3>
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets.
<h3>Destination XL Group's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Destination XL Group's revenue growth over 3 months faced difficulties. As of 31 July, 2024, the company experienced a decline of approximately -10.87%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Destination XL Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.91%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.53%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Destination XL Group's ROA stands out, surpassing industry averages. With an impressive ROA of 0.63%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Destination XL Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.13.
<a href="https://www.benzinga.com/quote/DXLG/earnings">To track all earnings releases for Destination XL Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXLG

Earnings Outlook For Destination XL Group

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 24.26% since its last report. The company recently reported that it has 888 thousand shares sold short, which is 1.78% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732197622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Molina Healthcare's Recent Short Interest

Mediaocean To Acquire Innovid For $3.15 Per Share In $500M Deal, Merging With Flashtalking To Create A Leading Independent Omnichannel Ad Tech Platform, Expected To Close In Early 2025

NuCana plunges after trial setback for cancer drug

Nucana (NCNA) has released an update. NuCana plc showcased positive results from its Phase 2 study of NUC-7738 in combination with pembrolizumab, o...

NuCana Reports Breakthrough in Resistant Melanoma Treatment

Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) today and set a price target of $25.00. The company'...

Oppenheimer Sticks to Their Buy Rating for Nucana (NCNA)

NuCana soars on positive data from mid-stage trial for its melanoma treatment

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Nucana (NCNA – Research Report) today. The company's shares closed yesterd...

Truist Financial Keeps Their Buy Rating on Nucana (NCNA)

Nucana (NCNA) has released an update. NuCana plc has announced the US Patent and Trademark Office granted a new patent for NUC-7738, a novel anti-c...

NuCana Secures US Patent for Promising Cancer Drug

Nucana (NCNA) has released an update. NuCana plc has updated its Prospectus Supplement to increase the maximum aggregate offering amount to $5.4 mi...

NuCana plc Enhances Offering to $5.4 Million

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Nucana (NCNA – Research Report), with a price...

Truist Financial Sticks to Their Buy Rating for Nucana (NCNA)

NuCana (NCNA) announced that initial data from the ongoing Phase 1b/2 modular study investigating NUC-3373 in combination with the PD-1 inhibitor p...

NuCana announces initial data from Phase 1b/2 modular study of NUC-3373

Nucana (NCNA) has released an update. NuCana's recent Phase 1b/2 study results reveal promising efficacy of its new drug NUC-3373 in combination wi...

NuCana's NUC-3373 Shows Promise in Cancer Treatment

RHHBF

RHHBY

Press Releases

NuCana Announces Completion of ADS Ratio Change

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

Health Care

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Legal

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Comments

NuCana

NuCana (NCNA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga